RMSF cases were identified from RMSF surveillance case report forms submitted to the Centers for Disease Control and Prevention (CDC) by state health departments and private physicians [1, 9] . Confirmed and probable cases with known outcomes (fatal or nonfatal) that were reported during 1981-1998 were selected for this study. A classification of "confirmed" RMSF required signs and symptoms compatible with disease (e.g., fever, headache, and rash) and at least 1 confirmatory laboratory finding. Criteria for laboratory confirmation based on serologic testing included a ^4-fold change in titer of antibody to R. rickettsii antigen between acuteand convalescent-phase serum specimens, measured by indirect immunofluorescence assay, complement fixation, latex agglutination, microagglutination, or indirect hemagglutination assay [9] . In addition, criteria for laboratory confirmation of RMSF included production of an amplicon of DNA using polymerase chain reaction assays with specific primers for/?, rickettsii; demonstration of rickettsial antigens by immunostaining of biopsy or autopsy tissues; or isolation of R. rickettsii from clinical specimens. A "probable" RMSF case was defined by clinically compatible symptoms and a single titer, measured by indirect immunofluorescence assay, of ^64; a single complement fixation titer of ^16; or another supportive serologic finding (^4-fold rise in titer or a single titer of ^320, reactive with Proteus OX-19 or OX-2 antigens [WeilFelix test], or a single titer of 5=128, measured by latex agglutination, indirect hemagglutination assay, or microagglutination test). Case reports that did not meet these criteria were considered to be "unconfirmed."
Demographic characteristics and clinical information for patients with fatal RMSF and patients with nonfatal RMSF were analyzed JID 2001; 184 (1 December) for the period 1981-1998 and for 2 separate 9-year intervals, 1981-1989 and 1990-1998. Characteristics for analyses included patient age, type of antibiotic treatment, geographic region of residence, clinical signs and symptoms at presentation, and number of days from onset of illness to treatment (onset-to-treatment interval). CFRs were calculated for these characteristics, and comparisons between patients with fatal RMSF and those with nonfatal RMSF were made using odds ratios (ORs) and 95 9c confidence intervals (CIs). Age groups included patients ^0 years and ^40 years old and, for additional analysis, groups of patients ^, 5-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, and ^70 years old. Treatment therapies were grouped by use of any tetracycline without chloramphenicol (tetracyclines only), chloramphenicol without a tetracycline (chloramphenicol only), both a tetracycline and chloramphenicol (both), and neither a tetracycline nor chloramphenicol (neither). Geographic regions of residence were the US Bureau of the Census regions (i.e., Northeast, Midwest, South, and West). The clinical triad for RMSF was defined as the presence of fever and rash and a history of tick attachment [3] . For patients treated with chloramphenicol or tetracycline, onset-to-treatment intervals were grouped as ^ days and ^5 days for analysis as a risk factor. Onset-to-treatment intervals for patients with fatal RMSF and patients with nonfatal RMSF were also compared by the Wilcoxon rank sum test [18] . To further evaluate antibiotic use, the difference in the frequency of use of tetracyclines and of chloramphenicol was compared by means of the ^ test. Hospitalization of patients was examined as a measure of severity of illness.
Multivariate logistic regression was done for the periods 1981-1998, 1981-1989, and 1990-1998 to further examine risk factors that were significantly associated with increased case fatality by fitting a series of hierarchical models to identify the best-fitting parsimonious model [19] . Risk factors were also examined separately for hospitalized patients and for patients with confirmed cases during 1981-1998. 1970s and the 1980s [1, 4, 5, 8, 14] . In this study, factors associated with death appeared to be consistent over time, with the following exceptions: the age for increased risk of death appeared to shift from patients h>40 years old during the 1980s to those >s60 years old during the 1990s, and the reported use of chloramphenicol for RMSF declined markedly and the use of tetracyclines increased during the 1990s, compared with use of these antibiotics during the 1980s. Treatment delay, which was identified as a risk factor in several other studies [ ing the relative efficacies of these drugs in humans. Chloramphenicol is still appropriate therapy for RMSF in some specialized situations [29] . Nonetheless, despite the limitations of incomplete and retrospectively collected data that are inherent to passive reporting, the findings from this study are consistent with and augment data from other epidemiologic analyses describing the superiority of tetracyclines over chloramphenicol as primary therapy for RMSF. Changes in treatment recommendations for pediatric patients and the removal of the oral formulation of chloramphenicol from the US market in 1995 likely contributed to the decrease in the use of chloramphenicol during the 1990s [1, 11, 12] . In this study, the decline in CFR from the 1980s to the 1990s, particularly among patients ^10 years old, may be associated in part with the decreased use of chloramphenicol and the increased use of tetracyclines for RMSF treatment in the 1990s. During the 1990s, children < 10 years old still received chloramphenicol as the primary therapy for RMSF more often than all other age groups, reflecting a continued need for physicians to be informed that doxycycline is the recommended treatment for RMSF in children [11, 12, 30 ].
Results

RMSF
An increased CFR among black individuals has been reported in other studies [4, 15] ; this has been ascribed to underreporting of nonfatal cases and increased misdiagnosis of RMSF among black individuals [4] or increased incidence of a glucosesphosphate dehydrogenase deficiency in this population [15] . However, as with earlier studies [1, 3] , the present study did not find a significant difference between CFRs for black individuals and white individuals.
The data from the national RMSF surveillance system have limitations. Although RMSF is a nationally notifiable disease [31] , fatal and nonfatal cases of RMSF can be missed and may pose a diagnostic dilemma for physicians in locations where the disease occurs infrequently [10, 11] . Moreover, state health departments may have differing criteria for defining and reporting RMSF cases, and some state health departments have revised their criteria for reporting RMSF cases to the CDC. Although criteria for reporting may change depending on the state, the specific data requested on and collected from case report forms have not changed since these forms were last modified, in 1981 [5] . In this context, risk factors identified in this study and earlier studies are limited to those data collected on the case report form [1, 17] , which accounts in part for the consistent appearance of particular risk factors (e.g., specific antibiotic use, onset-totreatment interval, and age). However, other risk factors (e.g., glucose-6-phosphate dehydrogenase deficiency) may not be identified in the surveillance case report form, because the form does not include specific queries about other medical conditions that may predispose patients to more-severe or fatal disease. The severity of the illness, which affects decisions about treatment and hospitalization, cannot be accurately ascertained with case report forms. Finally, the case report forms are not always fully completed and are completed with varying attention to detail. RMSF continues to be a potentially lethal threat throughout much of the United States, and recognized risk factors for total RMSF death are largely unchanged since the 1980s. Despite enhanced awareness of tickbome diseases during the 1980s and 1990s [16, [32] [33] [34] , diagnosis or treatment of RMSF may be delayed, and recommended treatment is not always administered; both of these situations may be associated with fatal consequences. Prompt treatment with tetracycline-class antibiotics within the first few days of onset of illness significantly reduces the risk of death [1, 11] . CFRs for RMSF in different geographic regions across the United States are similar, which suggests that, even in the region with the highest incidence of RMSF and, presumably, the greatest awareness of the disease (i.e., the South), treatment delays may occur and recommended therapy is not always provided. This observation suggests that, if deaths due to RMSF are to be further reduced in the United States, increased awareness and public health education regarding RMSF remain fundamental in achieving this goal.
